



Jeff Susman, MD Editor-in-Chief

EDITORIAL

The perils of PSA screening

his issue includes a Priority Update from the Research Literature (PURL) (page 357) that evaluates the results of 2 studies concerning PSA screening. No sooner had this PURL been completed than *The New England Journal of Medicine* (NEJM) published the results of a randomized controlled trial of radical prostatectomy vs watchful waiting in early prostate cancer, accompanied by an editorial titled, "Effective treatment for early-stage prostate cancer—possible, necessary, or both?" Meanwhile, we await the results of 2 trials being touted as definitive: the Prostate cancer Intervention Versus Observation Trial (PIVOT) and the Prostate testing for cancer and Treatment (ProtecT) trial.

Keeping up with this area of practice is beginning to feel like a full-time job. But I am going to go out on a limb here and suggest that, until we have fun-

Until we have new strategies for case finding or early intervention, let's stop this PSA screening nonsense. damentally changed strategies for targeted case finding or early intervention (think genomic and proteomic markers), it is time to stop this screening nonsense. The facts speak for themselves: A trial of 182,000 patients finds in a post hoc analysis of a very narrow population that death can be averted in one of 723 individuals who are screened.² What about the complications associated with diagnosis, work-up, and treatment?

It is time for urologists and primary care physicians to tell patients that PSA screening is unlikely to benefit them.

Some of you will suggest that we counsel patients about PSA testing to facilitate informed decision-making. But do we advise patients to play the lottery or try futile therapies?

The only men who stand to get even a small benefit from PSA screening are those in excellent health, and it is pretty darn hard to improve on that. I urge all of us to stop offering routine PSA testing and, when asked, to advise against this risky intervention.

ff (isman, M)
jfp@neoucom.edu

- Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ. 2010;341:c4543.
- 2. Crawford ED, Grubb R 3rd, Black A, et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. *J Clin Oncol.* 2011;29:355-361.
- $3. \ Bill-Axelson \ A, \ Holmberg \ L, \ Ruutu \ M, \ et \ al. \ Radical \ prostate ctomy \ versus \ watchful \ waiting \ in \ early \ prostate \ cancer. \ NEngl J Med. \ 2011; 364:1708-1717.$
- 4. Smith MR. Effective treatment for early-stage prostate cancer—possible, necessary, or both? N Engl J Med. 2011;364:1770-1772.
- Wilt TJ, Brawer MK, Barry MJ, et al. The Prostate cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials. 2009; 30:81-87.
- Lane JA, Hamdy FC, Martin RM, et al. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer. 2010;46:3095-3101.



EDITOR-IN-CHIEF

JEFFREY L. SUSMAN, MD Northeast Ohio Medical University, Rootstown

ASSOCIATE EDITORS

BERNARD EWIGMAN, MD, MSPH University of Chicago Pritzker School of Medicine

JOHN HICKNER, MD, MSc

Cleveland Clinic Medicine Institute

JOHN SAULTZ, MD

Oregon Health and Science University, Portland (Clinical Inquiries)

RICHARD P. USATINE, MD

University of Texas Health Sciences Center at San Antonio (*Photo Rounds*)

ASSISTANT EDITORS

DOUG CAMPOS-OUTCALT, MD, MPA

University of Arizona, Phoenix

GARY N. FOX, MD

St. Vincent Mercy Medical Center, Toledo, Ohio

RICK GUTHMANN, MD, MPH University of Illinois, Chicago

KEITH B. HOLTEN, MD

Berger Health System, Circleville, Ohio

GARY KELSBERG, MD, FAAFP University of Washington, Rentor

AUDREY PAULMAN MD MMM

University of Nebraska College of Medicine,

PAUL M. PAULMAN, MD

University of Nebraska College of Medicine

RICK RICER, MD

University of Cincinnat

E. CHRIS VINCENT, MD University of Washington, Seattle

EDITORIAL BOARD

FREDERICK CHEN, MD, MPH University of Washington, Seattle

LARRY CULPEPPER, MD, MPH

Boston University Medical Center

LINDA FRENCH, MD

University of Toledo

THEODORE G. GANIATS, MD University of California–San Diego, La Jolla

JEFFREY T. KIRCHNER, DO, FAAFP, AAHIVS

FRED MISER, MD, MA

The Ohio State University, Columbus

JANE L. MURRAY, MD

Sastun Center of Integrative Health Care, Overland Park, Kan

KEVIN PETERSON, MD, MPH University of Minnesota, St. Paul

GOUTHAM RAO, MD, MPA

University of Pittsburgh

DOUGLAS R. SMUCKER, MD, MPH

University of Cincinnati

JEFFREY R. UNGER, MD
Catalina Research Institute, Chino, Calif

BARBARA P. YAWN, MD, MSC Olmsted Medical Center, Rochester, Minn

DIRECT EDITORIAL INFORMATION AND INQUIRIES TO:

EDITORIAL OFFICE

Northeast Ohio Medical University 4209 State Route 44; PO Box 95 Rootstown, OH 44272

Telephone: (330) 325-6254

PUBLISHING OFFICES

Quadrant HealthCom, Inc.

7 Century Drive, Suite 302

Parsippany, NJ 07054

Telephone: (973) 206-3434; Fax: (973) 206-9378